US patents issued to Akaal Pharma on S1P1 receptor modulators useful for the treatment of autoimmune and inflammatory diseases
![](/46/pdcnewsitem/03/83/55/Akaal-Pharma-Logo.png)
Several similar patent applications have been filed in Canada, Europe, Japan, China and India.
Akaal Pharma has announced that the United States Patent and Trademark Office (USPTO) has issued Akaal Pharma the US Patents 9,181,182 B2, and 9,193,716 B2, entitled S1P receptors modulators, and S1P receptors modulators and their use thereof, respectively.
The patents cover Akaal Pharma’s internally discovered various classes of novel compounds (small molecule drug candidates) as modulators of Sphingosine 1-Phosphate receptors (S1P) useful in the treatment of autoimmune and inflammatory diseases. Novel chemical scaffolds, synthetic intermediates and processes for the manufacture of drug candidates are claimed in these issued composition-of-matter patents. Several similar patent applications have been filed in Canada, Europe, Japan, China and India. Nearly 50 million people are afflicted with various autoimmune and inflammatory diseases in the US alone.
“These issued patents strengthen our patent position and expand further the intellectual property discovered internally by Akaal Pharma’s medicinal chemistry and drug discovery team. We believe that novel small molecules claimed in these patents could provide new generation of safer and more effective small molecule drugs for the treatment of autoimmune and inflammatory diseases including psoriasis, atopic dermatitis, multiple sclerosis, ulcerative colitis, Crohn’s disease, stroke and others.” said Dale Dhanoa, CEO of Akaal Pharma.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance